# Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients

> **NCT02057003** · — · UNKNOWN · sponsor: **Valme University Hospital** · enrollment: 1000 (estimated)

## Conditions studied

- Hepatitis C, Chronic
- Human Immunodeficiency Virus

## Interventions

- **DRUG:** DAA against HCV

## Key facts

- **NCT ID:** NCT02057003
- **Lead sponsor:** Valme University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2016-10-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02057003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02057003, "Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02057003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*